United Therapeutics Corp (UTHR) 124.79 $UTHR
Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale
PR Newswire - Fri Sep 12, 8:10AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), United Therapeutics Corporation (NASDAQ: UTHR) and Brookdale Senior Living, Inc. (NYSE: BKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6426-100free.
Spectrum Pharmaceuticals to Advance Neutropenia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:20PM CDT
Spectrum Pharmaceuticals (SPPI) announced its intention to initiate a phase III study on SPI-2012 next year.
Uptrend Call Working As United Therapeutics Stock Rises 27.0% (UTHR)
Comtex SmarTrend(R) - Wed Sep 10, 9:54AM CDT
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on August 19th, 2014 at $93.35. In approximately 3 weeks, United Therapeutics has returned 27.02% as of today's recent price of $118.57.
United Therapeutics Set to Possibly Pullback After Yesterday's Rally of 2.05%
Comtex SmarTrend(R) - Tue Sep 09, 4:07PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $114.36 to a high of $121.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $115.63 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
United Therapeutics Rises 2.05% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Sep 09, 4:06PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $114.36 to a high of $121.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $115.63 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem's PLX-PAD Cells for Treatment of Pulmonary Arterial Hypertension
GlobeNewswire - Mon Sep 08, 2:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapy products, announced today that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase I study using Pluristem's PLacental eXpanded (PLX-PAD) cells in patients diagnosed with pulmonary arterial hypertension (PAH). PAH, with a global market estimated at approximately $3 billion, is characterized by abnormally high blood pressure in the arteries of the lungs; it can disrupt lung and heart function, leading to debilitating conditions such as heart failure.
Weakness Seen in Alcobra (ADHD): Stock Falls 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:40AM CDT
Alcobra saw a big move last session, as the company’s shares fell by almost 7% on the day.
The Zacks Analyst Blog Highlights: United Therapeutics, Repros Therapeutics, Amgen, Regeneron and Aegerion
PR Newswire - Thu Sep 04, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the United Therapeutics (Nasdaq:UTHR-Free Report), Repros Therapeutics (Nasdaq:RPRX-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report) and Aegerion (Nasdaq:AEGR-Free Report).
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 4:20PM CDT
Arena Pharmaceuticals, Inc. announced that its pulmonary arterial hypertensioncandidate APD811 has received orphan drug status from the FDA.
Shares of UTHR Up 23.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Sep 03, 9:19AM CDT
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on August 19th, 2014 at $93.35. In approximately 2 weeks, United Therapeutics has returned 23.34% as of today's recent price of $115.14.
Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 03, 9:10AM CDT
A favorable court ruling for United Therapeutics, positive late-stage data on a testosterone replacement treatment and the filing of the first BLA for a PCSK9 inhibitor were last week's highlights.
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
PR Newswire - Wed Sep 03, 8:20AM CDT
Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.
United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:25PM CDT
The U.S. District Court for the District of New Jersey has rendered a favorable decision in the Remodulin patent infringement lawsuit against Sandoz.
Critical Alerts For bluebird bio Inc., United Therapeutics Corporation, Mattel Inc, Ulta Salon Cosmetics & Fragrance Inc. and Applied Materials Inc. Released By InvestorsObserver
PR Newswire - Tue Sep 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BLUE, UTHR, MAT, ULTA and AMAT.
United Therapeutics (UTHR) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:57AM CDT
United Therapeutics (UTHR) Shares March Higher, Can It Continue?
Nasdaq stocks posting largest volume increases
AP - Fri Aug 29, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Fri Aug 29, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why United Therapeutics Corporation Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 29, 4:08PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of United Therapeutics , a biopharmaceutical...
United Therapeutics Legal Victory Sends Stock Flying
at Investor's Business Daily - Fri Aug 29, 3:21PM CDT
United Therapeutics (UTHR) scored a legal victory over Novartis' (NVS) generic-drug unit Sandoz in a 2-year-old patent case that will likely provide additional legal protection for United's Remodulin drug, which treats breathing problems for people...
Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale
PR Newswire - Fri Sep 12, 8:10AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), United Therapeutics Corporation (NASDAQ: UTHR) and Brookdale Senior Living, Inc. (NYSE: BKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6426-100free.
Spectrum Pharmaceuticals to Advance Neutropenia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:20PM CDT
Spectrum Pharmaceuticals (SPPI) announced its intention to initiate a phase III study on SPI-2012 next year.
Uptrend Call Working As United Therapeutics Stock Rises 27.0% (UTHR)
Comtex SmarTrend(R) - Wed Sep 10, 9:54AM CDT
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on August 19th, 2014 at $93.35. In approximately 3 weeks, United Therapeutics has returned 27.02% as of today's recent price of $118.57.
United Therapeutics Set to Possibly Pullback After Yesterday's Rally of 2.05%
Comtex SmarTrend(R) - Tue Sep 09, 4:07PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $114.36 to a high of $121.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $115.63 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
United Therapeutics Rises 2.05% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Sep 09, 4:06PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $114.36 to a high of $121.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $115.63 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem's PLX-PAD Cells for Treatment of Pulmonary Arterial Hypertension
GlobeNewswire - Mon Sep 08, 2:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapy products, announced today that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase I study using Pluristem's PLacental eXpanded (PLX-PAD) cells in patients diagnosed with pulmonary arterial hypertension (PAH). PAH, with a global market estimated at approximately $3 billion, is characterized by abnormally high blood pressure in the arteries of the lungs; it can disrupt lung and heart function, leading to debilitating conditions such as heart failure. Weakness Seen in Alcobra (ADHD): Stock Falls 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:40AM CDT
Alcobra saw a big move last session, as the company’s shares fell by almost 7% on the day.
The Zacks Analyst Blog Highlights: United Therapeutics, Repros Therapeutics, Amgen, Regeneron and Aegerion
PR Newswire - Thu Sep 04, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the United Therapeutics (Nasdaq:UTHR-Free Report), Repros Therapeutics (Nasdaq:RPRX-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report) and Aegerion (Nasdaq:AEGR-Free Report).
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 4:20PM CDT
Arena Pharmaceuticals, Inc. announced that its pulmonary arterial hypertensioncandidate APD811 has received orphan drug status from the FDA.
Shares of UTHR Up 23.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Sep 03, 9:19AM CDT
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on August 19th, 2014 at $93.35. In approximately 2 weeks, United Therapeutics has returned 23.34% as of today's recent price of $115.14.
Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 03, 9:10AM CDT
A favorable court ruling for United Therapeutics, positive late-stage data on a testosterone replacement treatment and the filing of the first BLA for a PCSK9 inhibitor were last week's highlights.
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
PR Newswire - Wed Sep 03, 8:20AM CDT
Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.
United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:25PM CDT
The U.S. District Court for the District of New Jersey has rendered a favorable decision in the Remodulin patent infringement lawsuit against Sandoz.
Critical Alerts For bluebird bio Inc., United Therapeutics Corporation, Mattel Inc, Ulta Salon Cosmetics & Fragrance Inc. and Applied Materials Inc. Released By InvestorsObserver
PR Newswire - Tue Sep 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BLUE, UTHR, MAT, ULTA and AMAT.
United Therapeutics (UTHR) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:57AM CDT
United Therapeutics (UTHR) Shares March Higher, Can It Continue?
Nasdaq stocks posting largest volume increases
AP - Fri Aug 29, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Fri Aug 29, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why United Therapeutics Corporation Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 29, 4:08PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of United Therapeutics , a biopharmaceutical...
United Therapeutics Legal Victory Sends Stock Flying
at Investor's Business Daily - Fri Aug 29, 3:21PM CDT
United Therapeutics (UTHR) scored a legal victory over Novartis' (NVS) generic-drug unit Sandoz in a 2-year-old patent case that will likely provide additional legal protection for United's Remodulin drug, which treats breathing problems for people...
